文献速递肝病胰腺与胆道疾病

原发性硬化性胆管炎患者定量MRCP与胆管疾病指标随时间变化的前瞻性研究

Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study.
PubMed 文献 · Aliment Pharmacol Ther · 2024-04-03

前瞻性扫描原发性硬化性胆管炎(PSC)患者,用MRCP+定量分析胆管直径、狭窄与扩张区域随时间的变化。基线时14项MRCP+指标在PSC与原发性胆汁性胆管炎、自身免疫性肝炎及健康对照间有显著差异;中位371天随访中29例PSC复查,15例MRCP+指标变化,狭窄数量随时间增加(p<0.05),而生化、弹性成像及放射科医生胆管造影评分无显著变化。

要点

  • 基线时14项定量MRCP+指标在PSC与疾病对照及健康对照间差异显著。
  • PSC基线狭窄数量、胆管数量及长度与MAS、瞬时弹性成像及血清ALP相关(p<0.01)。
  • 中位371天随访,29例PSC复查,15例MRCP+指标变化,狭窄数量增加(p<0.05)。

核心结论

  • 定量MRCP+可识别PSC患者胆管疾病随时间的变化,而生物化学、肝脏硬度及放射科医生胆管造影评估保持稳定。

研究设计与样本

  • 前瞻性研究,PSC患者接受非增强MRCP扫描,用MRCP+后处理软件计算定量指标。
  • 由对临床资料、生物化学及定量胆道指标盲态的肝胆胰放射科医生按改良阿姆斯特丹胆管造影评分(MAS)报告每份扫描。

主要发现

  • 基线时14项定量MRCP+指标在PSC患者(N=55)与原发性胆汁性胆管炎(N=55)、自身免疫性肝炎(N=57)及健康对照(N=18)间存在显著差异。
  • PSC中,基线量化狭窄数量及胆管数量和长度的指标与MAS、瞬时弹性成像及血清ALP值相关(所有相关性p<0.01)。
  • 中位371天随访(范围364-462天)内,29例PSC患者复查MRCP,其中15例MRCP+指标出现定量变化。
  • 与基线相比,定量MRCP+识别出狭窄数量随时间增加(p<0.05)。
  • 相比之下,生物化学、弹性成像或MAS在各时间点间无显著差异;非PSC肝病中定量MRCP+指标保持稳定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Imaging markers of biliary disease in primary sclerosing cholangitis (PSC) have potential for use in clinical and trial disease monitoring. Herein, we evaluate how quantitative magnetic resonance cholangiopancreatography (MRCP) metrics change over time, as per the natural history of disease. METHODS: Individuals with PSC were prospectively scanned using non-contrast MRCP. Quantitative metrics were calculated using MRCP+ post-processing software to assess duct diameters and dilated and strictured regions. Additionally, a hepatopancreatobiliary radiologist (blinded to clinical details, biochemistry and quantitative biliary metrics) reported each scan, including ductal disease assessment according to the modified Amsterdam Cholangiographic Score (MAS). RESULTS: At baseline, 14 quantitative MRCP+ metrics were found to be significantly different in patients with PSC (N = 55) compared to those with primary biliary cholangitis (N = 55), autoimmune hepatitis (N = 57) and healthy controls (N = 18). In PSC specifically, baseline metrics quantifying the number of strictures and the number and length of bile ducts correlated with the MAS, transient elastography and serum ALP values (p < 0.01 for all correlations). Over a median 371-day follow-up (range: 364-462), 29 patients with PSC underwent repeat MRCP, of whom 15 exhibited quantitative changes in MRCP+ metrics. Compared to baseline, quantitative MRCP+ identified an increasing number of strictures over time (p < 0.05). Comparatively, no significant differences in biochemistry, elastography or the MAS were observed between timepoints. Quantitative MRCP+ metrics remained stable in non-PSC liver disease. CONCLUSION: Quantitative MRCP+ identifies changes in ductal disease over time in PSC, despite stability in biochemistry, liver stiffness and radiologist-derived cholangiographic assessment (trial registration: ISRCTN39463479).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Trivedi PJ, Arndtz K, Abbas N, et al. Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study. Aliment Pharmacol Ther. 2024. PMID: 38571284. doi:10.1111/apt.17944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。